

Data Sharing Statement

The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. N Engl J Med. DOI: 10.1056/NEJMoa2021436.

| Question | Authors' Response |
|---|---|
| Will the data collected for your study be made available to others? | Yes |
| Would you like to offer context for your decision? | — |
| Which data? | Complete de-identified patient data set |
| Additional information about data | — |
| How or where can the data be obtained? | Please complete this form https://www.ndph.ox.ac.uk/files/about/data_access_enquiry_form_13_6_2019.docx and e-mail to: data.access@ndph.ox.ac.uk |
| When will data availability begin? | Within 3 months of complete 28-day follow-up. |
| When will data availability end? | — |
| Will any supporting documents be available? | — |
| Which supporting documents? | Informed Consent Form. Other |
| Additional information about supporting documents | Protocol, consent form, statistical analysis plan, definition & derivation of clinical characteristics & outcomes, training materials, regulatory documents, and other relevant study materials are available online at www.recoverytrial.net |
| How or where can supporting documents be obtained? | www.recoverytrial.net |
| When will supporting documents availability begin? | Immediately via study website |
| When will supporting documents availability end? | — |
| To whom will data be available? | The applicant must be a bona fide researcher registered with an appropriate institution |
| For what type of analysis or purpose? | Data will be made available in line with the policy and procedures described at: https://www.ndph.ox.ac.uk/data-access |
| By what mechanism? | Data will be made available in line with the policy and procedures described at: https://www.ndph.ox.ac.uk/data-access |

| | |
|-------------------------|--|
| Any other restrictions? | — |
| Additional information | In line with the approved protocol, the Steering Committee will facilitate the use of the study data and approval will not be unreasonably withheld. However, the Steering Committee will need to be satisfied that any proposed publication is of high quality, honours the commitments made to the study participants in the consent documentation and ethical approvals, and is compliant with relevant legal and regulatory requirements (e.g. relating to data protection and privacy). The Steering Committee will have the right to review and comment on any draft manuscripts prior to publication. |

This statement was posted on July 17, 2020, at [NEJM.org](https://www.nejm.org).